Výsledky vyhledávání

Akademický článek

Regorafenib with immunotherapy versus regorafenib alone as second‐line treatment for hepatocellular carcinoma: A multicenter real‐world study.

Autor: Qiao, Liang^1,2 (AUTHOR), He, Wei^1,2 (AUTHOR), Wang, Guoying^3,4 (AUTHOR), Chen, Huanwei⁵ (AUTHOR), Huang, Fuxi⁶ (AUTHOR), Zhang, Bo⁷ (AUTHOR), Qiu, Yuxiong^1,2 (AUTHOR), Liu, Shaoru^1,2 (AUTHOR), Huang, Zhenkun^1,2 (AUTHOR), Yuan, Yichuan^1,2 (AUTHOR), Qiu, Jiliang^1,2 (AUTHOR), Yuan, Yunfei^1,2 (AUTHOR) yuanyf@mail.sysu.edu.cn, Li, Binkui^1,2 (AUTHOR) libk@sysucc.org.cn

Publikováno v: Cancer Medicine. May2024, Vol. 13 Issue 9, p1-13. 13p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer.

Autor: Bajpai, Prachi¹ (AUTHOR), Agarwal, Sumit¹ (AUTHOR), Afaq, Farrukh¹ (AUTHOR), Al Diffalha, Sameer^1,2 (AUTHOR), Chandrashekar, Darshan S.¹ (AUTHOR), Kim, Hyung-Gyoon¹ (AUTHOR), Shelton, Abigail¹ (AUTHOR), Miller, C. Ryan^1,2 (AUTHOR), Singh, Santosh K.³ (AUTHOR), Singh, Rajesh³ (AUTHOR), Varambally, Sooryanarayana^1,2 (AUTHOR), Nagaraju, Ganji Purnachandra⁴ (AUTHOR), Manne, Ashish⁵ (AUTHOR), Paluri, Ravi⁶ (AUTHOR), Khushman, Moh'd⁷ (AUTHOR), Manne, Upender^1,2 (AUTHOR) upendermanne@uabmc.edu

Publikováno v: Journal of Experimental & Clinical Cancer Research (17569966). 7/11/2024, Vol. 43 Issue 1, p1-18. 18p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

CircDCAF8 promotes the progression of hepatocellular carcinoma through miR-217/NAP1L1 Axis, and induces angiogenesis and regorafenib resistance via exosome-mediated transfer.

Autor: Gong, Jiahao^1,2 (AUTHOR), Han, Guoyong^1,2 (AUTHOR), Chen, Zhiqiang^1,2 (AUTHOR), Zhang, Yinqi^1,2 (AUTHOR), Xu, Bin³ (AUTHOR), Xu, Chao^1,2 (AUTHOR), Gao, Wen⁴ (AUTHOR) gaowen@jsph.org.cn, Wu, Jindao^1,2 (AUTHOR) wujindao@njmu.edu.cn

Publikováno v: Journal of Translational Medicine. 5/30/2024, Vol. 22, p1-20. 20p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Regorafenib versus Cetuximab plus Irinotecan in Third-line Metastatic Colorectal Cancer in Iran: A Model-based Cost-utility Analysis.

Autor: Seyedifar, Meysam¹, Fatemi, Behzad² B-fatemi@farabi.tums.ac.ir, Soleymani, Fatemeh¹, Sabouri, Menhajuddin¹

Publikováno v: Middle East Journal of Cancer. Oct2024, Vol. 15 Issue 4, p324-332. 9p.

Zobrazit plný text záznamu

Akademický článek

Quality by design enabled formulation development of regorafenib monohydrate loaded PEGylated PLGA polymeric nanoparticles: Enhanced oral bioavailability and biopharmaceutical attributes.

Autor: Panigrahi, Dhananjay¹, Swain, Suryakanta² swain_suryakant@yahoo.co.in, Sahu, Pratap Kumar¹, Ghose, Debashish³, Jena, Bikash Ranjan⁴

Publikováno v: Nanomedicine Journal. Autumn2024, Vol. 11 Issue 4, p401-416. 16p.

Zobrazit plný text záznamu

Akademický článek

An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review.

Autor: Darmadi, Darmadi¹ darmadi@usu.ac.id, Sungkar, Taufik¹, Pakpahan, Cennikon², Surja, Sem Samuel³

Publikováno v: Acta Medica Academica. Apr2024, Vol. 53 Issue 1, p46-58. 13p.

Zobrazit plný text záznamu

Akademický článek

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.

Autor: Taşçı, Elif Şenocak¹ (AUTHOR) esenocak@gmail.com, Oyan, Başak² (AUTHOR), Sönmez, Özlem² (AUTHOR), Mutlu, Arda Ulaş² (AUTHOR), Atcı, Muhammed Mustafa³ (AUTHOR), Sakin, Abdullah⁴ (AUTHOR), Öner, İrem⁵ (AUTHOR), Çınkır, Havva Yeşil⁶ (AUTHOR), Eryılmaz, Melek Karakurt⁷ (AUTHOR), Çağlayan, Dilek⁷ (AUTHOR), Balçık, Onur Yazdan⁸ (AUTHOR), Paksoy, Nail⁹ (AUTHOR), Karabulut, Senem¹⁰ (AUTHOR), Salim, Derya Kıvrak¹¹ (AUTHOR), Bilir, Cemil¹² (AUTHOR), Özen, Miraç¹³ (AUTHOR), Özçelik, Melike¹⁴ (AUTHOR), Arıcan, Ali² (AUTHOR), Akagündüz, Baran¹⁵ (AUTHOR), İnal, Ali¹⁶ (AUTHOR)

Publikováno v: BMC Cancer. 1/22/2024, Vol. 24 Issue 1, p1-10. 10p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo.

Autor: Ji, Yanhao¹ (AUTHOR), Harris, Michael A.^1,2 (AUTHOR), Newton, Lucas M.^1,3 (AUTHOR), Harris, Tiffany J.⁴ (AUTHOR), Fairlie, W. Douglas^1,4,5 (AUTHOR), Lee, Erinna F.^1,4,5 (AUTHOR), Hawkins, Christine J.^1,2 (AUTHOR) c.hawkins@latrobe.edu.au

Publikováno v: BMC Cancer. 11/4/2024, Vol. 24 Issue 1, p1-14. 14p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro Sampling.

Autor: Morelli, Mariangela¹ (AUTHOR) f.lessi@fpscience.it, Lessi, Francesca¹ (AUTHOR) s.franceschi@fpscience.it, Franceschi, Sara¹ (AUTHOR) m.giacomarra@fpscience.it, Ferri, Gianmarco¹ (AUTHOR) c.mazzanti@fpscience.it, Giacomarra, Manuel¹ (AUTHOR), Menicagli, Michele¹ (AUTHOR), Gambacciani, Carlo² (AUTHOR) orazio.santonocito@uslnordovest.toscana.it, Pieri, Francesco² (AUTHOR), Pasqualetti, Francesco³ (AUTHOR), Montemurro, Nicola⁴ (AUTHOR) nicola.montemurro@unipi.it, Aretini, Paolo¹ (AUTHOR), Santonocito, Orazio Santo² (AUTHOR), Di Stefano, Anna Luisa² (AUTHOR), Mazzanti, Chiara Maria¹ (AUTHOR)

Publikováno v: Cells (2073-4409). Mar2024, Vol. 13 Issue 6, p487. 19p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Diabetes Mellitus Induced by Nivolumab plus Regorafenib in a Patient with Esophageal Cancer.

Autor: Mei-Chen Lin¹ maylin0505@gmail.com, Li-Yuan Bai^1,2, Shih-Peng Yeh¹, Chang-Fang Chiu^1,2,3, Ming-Yu Lien^1,2,4

Publikováno v: Journal of Cancer Research & Practice. Apr-Jun2024, Vol. 11 Issue 2, p81-84. 4p.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání